Cargando…

Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody

Multidrug-resistant Neisseria gonorrhoeae is a global health problem. Monoclonal antibody (mAb) 2C7 recognizes a gonococcal lipooligosaccharide epitope that is expressed by >95% of clinical isolates and hastens gonococcal vaginal clearance in mice. Chimeric mAb 2C7 (human immunoglobulin G1 [IgG1]...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulati, Sunita, Beurskens, Frank J., de Kreuk, Bart-Jan, Roza, Marcel, Zheng, Bo, DeOliveira, Rosane B., Shaughnessy, Jutamas, Nowak, Nancy A., Taylor, Ronald P., Botto, Marina, He, Xianbao, Ingalls, Robin R., Woodruff, Trent M., Song, Wen-Chao, Schuurman, Janine, Rice, Peter A., Ram, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602280/
https://www.ncbi.nlm.nih.gov/pubmed/31216278
http://dx.doi.org/10.1371/journal.pbio.3000323
_version_ 1783431355773747200
author Gulati, Sunita
Beurskens, Frank J.
de Kreuk, Bart-Jan
Roza, Marcel
Zheng, Bo
DeOliveira, Rosane B.
Shaughnessy, Jutamas
Nowak, Nancy A.
Taylor, Ronald P.
Botto, Marina
He, Xianbao
Ingalls, Robin R.
Woodruff, Trent M.
Song, Wen-Chao
Schuurman, Janine
Rice, Peter A.
Ram, Sanjay
author_facet Gulati, Sunita
Beurskens, Frank J.
de Kreuk, Bart-Jan
Roza, Marcel
Zheng, Bo
DeOliveira, Rosane B.
Shaughnessy, Jutamas
Nowak, Nancy A.
Taylor, Ronald P.
Botto, Marina
He, Xianbao
Ingalls, Robin R.
Woodruff, Trent M.
Song, Wen-Chao
Schuurman, Janine
Rice, Peter A.
Ram, Sanjay
author_sort Gulati, Sunita
collection PubMed
description Multidrug-resistant Neisseria gonorrhoeae is a global health problem. Monoclonal antibody (mAb) 2C7 recognizes a gonococcal lipooligosaccharide epitope that is expressed by >95% of clinical isolates and hastens gonococcal vaginal clearance in mice. Chimeric mAb 2C7 (human immunoglobulin G1 [IgG1]) with an E430G Fc modification that enhances Fc:Fc interactions and hexamerization following surface-target binding and increases complement activation (HexaBody technology) showed significantly greater C1q engagement and C4 and C3 deposition compared to mAb 2C7 with wild-type Fc. Greater complement activation by 2C7-E430G Fc translated to increased bactericidal activity in vitro and, consequently, enhanced efficacy in mice, compared with “Fc-unmodified” chimeric 2C7. Gonococci bind the complement inhibitors factor H (FH) and C4b-binding protein (C4BP) in a human-specific manner, which dampens antibody (Ab)-mediated complement-dependent killing. The variant 2C7-E430G Fc overcame the barrier posed by these inhibitors in human FH/C4BP transgenic mice, for which a single 1 μg intravenous dose cleared established infection. Chlamydia frequently coexists with and exacerbates gonorrhea; 2C7-E430G Fc also proved effective against gonorrhea in gonorrhea/chlamydia-coinfected mice. Complement activation alone was necessary and sufficient for 2C7 function, evidenced by the fact that (1) “complement-inactive” Fc modifications that engaged Fc gamma receptor (FcγR) rendered 2C7 ineffective, nonetheless; (2) 2C7 was nonfunctional in C1q(−/−) mice, when C5 function was blocked, or in C9(−/−) mice; and (3) 2C7 remained effective in neutrophil-depleted mice and in mice treated with PMX205, a C5a receptor (C5aR1) inhibitor. We highlight the importance of complement activation for antigonococcal Ab function in the genital tract. Elucidating the correlates of protection against gonorrhea will inform the development of Ab-based gonococcal vaccines and immunotherapeutics.
format Online
Article
Text
id pubmed-6602280
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-66022802019-07-12 Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody Gulati, Sunita Beurskens, Frank J. de Kreuk, Bart-Jan Roza, Marcel Zheng, Bo DeOliveira, Rosane B. Shaughnessy, Jutamas Nowak, Nancy A. Taylor, Ronald P. Botto, Marina He, Xianbao Ingalls, Robin R. Woodruff, Trent M. Song, Wen-Chao Schuurman, Janine Rice, Peter A. Ram, Sanjay PLoS Biol Research Article Multidrug-resistant Neisseria gonorrhoeae is a global health problem. Monoclonal antibody (mAb) 2C7 recognizes a gonococcal lipooligosaccharide epitope that is expressed by >95% of clinical isolates and hastens gonococcal vaginal clearance in mice. Chimeric mAb 2C7 (human immunoglobulin G1 [IgG1]) with an E430G Fc modification that enhances Fc:Fc interactions and hexamerization following surface-target binding and increases complement activation (HexaBody technology) showed significantly greater C1q engagement and C4 and C3 deposition compared to mAb 2C7 with wild-type Fc. Greater complement activation by 2C7-E430G Fc translated to increased bactericidal activity in vitro and, consequently, enhanced efficacy in mice, compared with “Fc-unmodified” chimeric 2C7. Gonococci bind the complement inhibitors factor H (FH) and C4b-binding protein (C4BP) in a human-specific manner, which dampens antibody (Ab)-mediated complement-dependent killing. The variant 2C7-E430G Fc overcame the barrier posed by these inhibitors in human FH/C4BP transgenic mice, for which a single 1 μg intravenous dose cleared established infection. Chlamydia frequently coexists with and exacerbates gonorrhea; 2C7-E430G Fc also proved effective against gonorrhea in gonorrhea/chlamydia-coinfected mice. Complement activation alone was necessary and sufficient for 2C7 function, evidenced by the fact that (1) “complement-inactive” Fc modifications that engaged Fc gamma receptor (FcγR) rendered 2C7 ineffective, nonetheless; (2) 2C7 was nonfunctional in C1q(−/−) mice, when C5 function was blocked, or in C9(−/−) mice; and (3) 2C7 remained effective in neutrophil-depleted mice and in mice treated with PMX205, a C5a receptor (C5aR1) inhibitor. We highlight the importance of complement activation for antigonococcal Ab function in the genital tract. Elucidating the correlates of protection against gonorrhea will inform the development of Ab-based gonococcal vaccines and immunotherapeutics. Public Library of Science 2019-06-19 /pmc/articles/PMC6602280/ /pubmed/31216278 http://dx.doi.org/10.1371/journal.pbio.3000323 Text en © 2019 Gulati et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gulati, Sunita
Beurskens, Frank J.
de Kreuk, Bart-Jan
Roza, Marcel
Zheng, Bo
DeOliveira, Rosane B.
Shaughnessy, Jutamas
Nowak, Nancy A.
Taylor, Ronald P.
Botto, Marina
He, Xianbao
Ingalls, Robin R.
Woodruff, Trent M.
Song, Wen-Chao
Schuurman, Janine
Rice, Peter A.
Ram, Sanjay
Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody
title Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody
title_full Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody
title_fullStr Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody
title_full_unstemmed Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody
title_short Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody
title_sort complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6602280/
https://www.ncbi.nlm.nih.gov/pubmed/31216278
http://dx.doi.org/10.1371/journal.pbio.3000323
work_keys_str_mv AT gulatisunita complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT beurskensfrankj complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT dekreukbartjan complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT rozamarcel complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT zhengbo complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT deoliveirarosaneb complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT shaughnessyjutamas complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT nowaknancya complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT taylorronaldp complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT bottomarina complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT hexianbao complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT ingallsrobinr complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT woodrufftrentm complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT songwenchao complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT schuurmanjanine complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT ricepetera complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody
AT ramsanjay complementalonedrivesefficacyofachimericantigonococcalmonoclonalantibody